BRÈVE

sur CureVac (NASDAQ:CVAC)

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

Graphique de l'évolution du cours de l'action CureVac (EBR:CVAC).

GSK plc and CureVac N.V. have announced a restructuring of their existing collaboration into a new licensing agreement. GSK will gain full rights to develop, manufacture, and commercialize mRNA candidate vaccines for influenza and COVID-19 globally.

Under the terms, CureVac will receive €400 million upfront and up to €1.05 billion in development, regulatory, and sales milestones. The new agreement replaces all previous financial considerations from their prior collaboration.

Since 2020, GSK and CureVac have been developing mRNA vaccines for infectious diseases, with promising candidates for seasonal influenza and COVID-19 currently in Phase 2 clinical trials.

GSK's Chief Scientific Officer, Tony Wood, expressed enthusiasm for developing best-in-class mRNA vaccines. CureVac's CEO, Alexander Zehnder, highlighted the strong financial position this agreement provides to focus on building a robust R&D pipeline.

The completion of the agreement is subject to antitrust and regulatory approvals and customary closing conditions.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de CureVac